thebell

전체기사

PDC*line Pharma seeks to go public in Korea Belgian-French clinical-stage biotech firm to become first European company listed here

Translated by Kim So-in 공개 2022-05-23 08:08:14

이 기사는 2022년 05월 23일 08:06 더벨 유료페이지에 표출된 기사입니다.

PDC*line Pharma is seeking to go public in South Korea next year to become the first European company to list its shares here.

Founded in 2014 as a spin-off from the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line).

The company aims to go public in Korea next year, according to industry sources on Friday. There are two overseas companies listed on the country’s main bourse Kospi and 21 on the junior Kosdaq market, according to Korea Exchange.

Most recently, U.S.-based NeoImmuneTech and Singapore-based Prestige Biopharma made there market debuts here.

All foreign biotech firms listed on the domestic stock market are their Korean subsidiaries. They all collaborated with domestic personnel during their listing processes. In PDC*line Pharma’s case, the Belgian-French biotech company itself is going public.

The company has hired Mirae Asset Securities to handle the IPO process. PDC*line Pharma is considering to carry out its listing via the country’s special track like other domestic biotech firms did.

PDC*line Pharma completed its Series B2 round of financing in December 2021, raising a total of €17.5 million (23 billion won) from Belgian and South Korean investors.

The financing round was led by Korea Investment Partners and involved a syndicate of new South Korean investors in life sciences: Alpha Holdings, Brain Asset Management and Hansong Neotech.

Existing investors also participated: Noshaq Group, Sambrinvest, SFPI-FPIM (the Belgian Federal Holding and Investment Company) and SRIW (The Regional Investment Company of Wallonia). The proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer. (Reporting by Joon-woo Nam)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재 및 재배포 금지 >

더벨 서비스 문의

02-724-4102

유료 서비스 안내
주)더벨 주소서울특별시 중구 무교로 6 (을지로 1가) 금세기빌딩 5층대표/발행인성화용 편집인이진우 등록번호서울아00483
등록년월일2007.12.27 / 제호 : 더벨(thebell) 발행년월일2007.12.30청소년보호관리책임자김용관
문의TEL : 02-724-4100 / FAX : 02-724-4109서비스 문의 및 PC 초기화TEL : 02-724-4102기술 및 장애문의TEL : 02-724-4159

더벨의 모든 기사(콘텐트)는 저작권법의 보호를 받으며, 무단 전재 및 복사와 배포 등을 금지합니다.

copyright ⓒ thebell all rights reserved.